Core Insights - Nasus Pharma has entered into a strategic collaboration with Aptar, a leading global manufacturer of drug delivery systems, to enhance the clinical and commercial development of its intranasal powder epinephrine product candidate, NS002 [1][2] Group 1: Collaboration Details - The collaboration provides Nasus Pharma with access to Aptar's proven Unit Dose System technology, which will support the development and commercialization of NS002 [2] - This partnership aims to leverage Aptar's regulatory pathways, manufacturing capabilities, and supply chain to accelerate NS002's market entry while minimizing development risks [2] Group 2: Product Information - NS002 is being developed as a needle-free alternative to traditional epinephrine autoinjectors for patients experiencing anaphylaxis, focusing on rapid drug delivery in emergency situations [3] - The proprietary powder-based intranasal (PBI) technology is designed for quick absorption through the nasal cavity, utilizing uniform spherical powder particles for enhanced dispersion and absorption compared to liquid-based products [3]

Core Insights - Nasus Pharma Ltd. has successfully listed on the New York Stock Exchange and celebrated this milestone by ringing the Closing Bell on August 25, 2025, highlighting its commitment to transforming emergency medicine through innovative intranasal therapies [1][2][3] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products aimed at treating acute medical conditions, particularly severe allergic reactions and anaphylaxis [4] - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional Epinephrine autoinjectors [4] Technology and Innovation - The proprietary powder-based intranasal (PBI) technology developed by Nasus Pharma is intended for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles to ensure broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Leadership and Vision - The CEO of Nasus Pharma, Dan Teleman, emphasized the company's dedication to innovation and its mission to develop life-saving treatments that are easy to use and accessible during emergencies [3]